Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 ...
Pfizer's management team recently announced sales and earnings expectations for 2025. An investment-bank analyst thinks Pfizer stock can shoot about 37% higher in 2025. Pfizer has raised its ...
Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...
As one of the largest vaccine makers, Pfizer has a big part of its business hinging on potential immunization policy changes under the incoming Trump administration. So when vaccine skeptic Robert F.
After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.
Pfizer (NYSE:PFE) just dropped some solid news for investors: 2025 revenue projections are right where Wall Street expected, between $61 billion and $64 billion, with adjusted earnings per share ...
Pfizer CEO met RFK Jr. and Trump, developed good relationship Trump committed to reforming pharmacy benefit managers, reducing medicine costs Pfizer faces investor pressure over strategy, shares ...
Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the call, Goldman Sachs has outlined its expectations for the guide and ...
Beata Zawrzel / NurPhoto via Getty Images Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.
Bonus Jun 12, 2000 Jun 28, 2000 May 25, 2000 Bonus Ratio: 1 share(s) for every 1 shares held Bonus--Jul 25, 1977 Bonus Ratio: 4 share(s) for every 5 shares held Bonus--Jul 25, 1972 Bonus Ratio: 2 ...